Document is current

Article History

Received: 25 January 2025

Accepted: 29 January 2025

First Online: 2 April 2025

Declarations

:

: All authors have declared no conflicts of interest regarding this article. Potential financial interests exist for MP: research funding, advisory board, honorarium, or travel expenses from Astra Zeneca, Glaxo Smith Kline, MSD. PW: has received research funding from Amgen, AstraZeneca, MSD, GlaxoSmithKline, Novartis, Pfizer, Roche Pharma, Clovis, Lilly, and honoraria from Amgen, AstraZeneca, MSD, GlaxoSmithKline, Novartis, Pfizer, Roche Pharma, Clovis, TEVA, Eisai, Lilly, Gilead, and Daichii Sankyo. PW serves on the advisory boards of Amgen, AstraZeneca, MSD, GlaxoSmithKline, Novartis, Pfizer, Roche Pharma, Clovis, TEVA, Eisai, Lilly, Gilead, and Daichii Sankyo; IMH: has received support from PlantTec, Tesaro/GSK, MSD as a member of advisory boards, from MSD, Tesaro/GSK and Roche for venue support and unrestricted research grants from Gedeon Richter, Bayer, Jenapharm, Takeda, Storz and PlantTec.; IR: no conflict; SST: received honoraria for speakers from Pfizer, Roche, and author fees from Thieme, with the continuing education supported by GSK and Celgene; SM: Research funding, advisory board, honoraria, or travel grants: AbbVie, AstraZeneca, Clovis, Eisai, GlaxoSmithKline, Hubro, Immunogen, Medac, MSD, Novartis, Nykode, Olympus, PharmaMar, Pfizer, Roche, Seagen, Sensor Kinesis, and Teva; CG: Consultant: Abbvie, AstraZeneca, Celgene, Clovis, Eisai, GSK, MSD, PharmaMar, Roche, Vifor Pharma, Sandoz; Speaker: Abbvie, Amgen, AstraZeneca, Eisai, GSK, MSD, PharmaMar, Roche, Sandoz; Direct research funding: AstraZeneca, Meda Pharma, Roche Diagnostics;Travel/meeting support: AstraZeneca, GSK, MSD, PharmaMar, Roche, Roche Diagnostics; VHS: no conflict; AH: honoraria for speakers from AstraZeneca, Celgene, GSK, LEO Pharma, Lilly Deutschland, MedConcept GmbH, Med Update GmbH, Pfizer, MSD, PharmaMar, Pierre Fabre Pharma, Roche Pharma AG. For advisory boards and consultancy services: AstraZeneca, GSK, LEO Pharma, MSD, PharmaMar, Roche Pharma AG, Streamedup! GmbH, and Tesaro Bio Germany GmbH; JS: Research Funding: Roche Pharma, AstraZeneca, Bayer, Clovis Oncology, GlaxoSmith, Lilly, Tesaro, Iqvia, Mural, MSD; Honorary: Tesaro, GlaxoSmith, PharmaMar, AstraZeneca, Clovis Oncology, Bayer, Roche Pharma, Vifor Pharma, Hexal AG, Novartis Pharma, Eisai, Esteve Pharmaceuticals, Incyte Biosciences, Phytolife Nutrition, JenaPharm, Kyowa Kirin, Oncoinvent AS, Daiichi, Medtronic Covidien, AMGEN; Consulting: Tesaro, Merck /Pfizer, PharmaMar, Clovis Oncology, AstraZeneca, Roche Pharma; GlaxoSmith, MSD, Eisai, Novocure, Oncoinvent, Intuitive Surgical, Seagan, Bayer Vital, Mundipharma, Sanofi-Aventis Deutschland GmbH, Immunogen, Tubulis GmbH, Daiichi Sankyo, Bristol Myers, Karyopharm Therpeutics.